India’s largest multispecialty hospital network by bed capacity hits the market with a Rs 9,275 crore issue — the biggest healthcare IPO India has seen — priced at the upper band of Rs 590.
Manipal Health Enterprises Ltd. (MHEL), the flagship hospital network of the Manipal Group, opens for subscription on July 29 with the issue closing on July 31. The company operates India’s largest pan-India multispecialty hospital network by licensed bed capacity and the second largest by number of hospitals.
The issue is a landmark for the Indian healthcare sector — at Rs 9,275 crore, it is the largest hospital IPO India has seen, and the maiden public offering from the storied Manipal Group, which traces its origins to the late T.M.A. Pai. The grey market premium ahead of the opening was in the Rs 9–25 range.
What the Company Does
Manipal Health operates 49 hospitals with 13,037 licensed beds across 14 states and union territories as of March 31, 2026. It is the only private hospital chain to lead simultaneously in three of India’s largest metro markets — Bengaluru (5,376 beds across 26 hospitals in the three metros), Kolkata (West Bengal), and Pune (Maharashtra) — by bed capacity. It maintains a balanced urban-rural mix, with 46.78% of beds in metros and 53.22% in non-metro markets, and served 7.63 million patients across its network in FY26.
The company offers a comprehensive range of care — from outpatient to complex tertiary and quaternary procedures — across specialties including oncology, cardiology, neurosciences, orthopaedics, transplants, and robotic surgery. As of March 31, 2026, it had 11,064 doctors available to provide services and 24,240 employees on its payroll, making it one of India’s largest private healthcare employers.
Its regional dominance is significant: MHEL is the largest private hospital player in Karnataka, Maharashtra and Goa, and in select eastern states including West Bengal, Odisha, Jharkhand, and Sikkim. For FY26, it reported the second-highest revenue from operations among private hospital chains in India.
Issue Details
| Particulars | Details |
|---|---|
| Issue Opens | July 29, 2026 |
| Issue Closes | July 31, 2026 |
| Listing | BSE and NSE (August 5, 2026) |
| Price Band | Rs 560 – Rs 590 per share |
| Face Value | Rs 2 |
| Total Issue Size | Rs 9,275.22 crore |
| Fresh Issue | Rs 8,000 crore |
| Offer for Sale | Rs 1,275.22 crore |
| Minimum Application | 25 shares |
| Min. Retail Investment | Rs 14,750 |
| Employee Discount | Rs 56 per share |
| Post-IPO Market Cap | Rs 77,605.68 crore |
| Issue Constitutes | 11.95% of post-IPO paid-up equity |
| Retail / HNI / QIB | 10% / 15% / 75% |
| BRLMs | Kotak Mahindra Capital, Axis Capital, Goldman Sachs, Jefferies India, J.P. Morgan India, UBS Securities India, DBS Bank India |
| Registrar | KFin Technologies Ltd. |
Objects of the Issue
| Object | Amount (Rs crore) |
|---|---|
| Repayment / prepayment of borrowings | 5,552.76 |
| Acquisition of minority stake in Sahyadri Hospitals Pvt. Ltd. | 574.00 |
| General corporate purposes | Balance |
The debt repayment component is transformational — management has stated that after prepayment, MHEL will be debt-free, generating significant savings on finance costs and improving future PAT margins.
Financial Performance
| Particulars (Rs cr) | FY24 | FY25 | FY26 |
|---|---|---|---|
| Total Income | 6,265.17 | 8,362.79 | 10,520.51 |
| Net Profit | 533.20 | 1,081.67 | 916.52 |
| PAT Margin | 8.64% | 13.12% | 8.87% |
| RoCE | 27.74% | 26.98% | 21.88% |
The revenue trajectory is strong — from Rs 6,265 crore in FY24 to Rs 10,521 crore in FY26, a 68% increase in two years. However, the FY26 profit picture is more nuanced: PAT declined from Rs 1,081.67 crore in FY25 to Rs 916.52 crore in FY26 despite the higher revenue base, driven by higher employee costs, finance costs, depreciation and amortisation, and exceptional provisions incurred during the expansion phase. Management attributes this to ongoing hospital additions and capacity buildout — a temporary margin compression that is expected to improve as debt is repaid and new facilities stabilise.
Average EPS over three years is Rs 7.82 (basic) and average RoNW is 13.80%.
Valuation and Peer Comparison
At the upper band of Rs 590, the issue is priced at a P/E of 84.65x on FY26 earnings and 71.78x on FY25 earnings, and at a P/BV of 8.13x on pre-IPO NAV of Rs 72.55 and 4.66x on post-IPO NAV of Rs 126.56.
| Listed Peer | P/E (as of July 24, 2026) |
|---|---|
| Apollo Hospitals | 64.6x |
| Fortis Healthcare | 67.8x |
| Max Healthcare | 70.9x |
| Manipal Health (IPO price) | 84.65x (FY26) |
Manipal Health enters at a premium to all three listed hospital peers — understandable partly because this is the maiden offering from one of India’s most recognised healthcare brands, and because the post-debt-repayment earnings profile is meaningfully higher than FY26 actuals. The fully diluted EPS on a debt-free basis would be materially better.
Grey market premium as of the opening date stands at approximately Rs 9–13 per share — a modest 1.5–2.2% over the upper price band — well below the Rs 50 peak seen in late July, indicating measured rather than aggressive listing expectations.
Risks to Consider
The FY26 profit decline — despite strong revenue growth — is the central concern entering this IPO. Higher employee costs and finance costs in FY26 reflect the scale of MHEL’s ongoing expansion, but investors are pricing in a recovery that depends on execution: debt repayment materialising on schedule, new hospitals reaching normalised occupancy, and cost structures stabilising.
The hospital industry is capital-intensive, regulated, and sensitive to doctor availability and reputation. MHEL’s geographic concentration in South and East India — particularly Karnataka — means any regional competitive pressure or regulatory shift disproportionately affects the group. The company has not paid any dividends in the reported periods, and with large debt repayment obligations consuming the fresh issue proceeds, near-term dividend returns are unlikely.
Analyst View
Analysts note that MHEL is a pan-India operator with an established multispecialty network and genuine scale advantages, and that revenue has grown strongly across all reported periods. However, margin pressure in FY26 following higher provisions and expansion costs is a near-term concern, and the issue appears aggressively priced based on current earnings.
Post-listing, the stock may catch fancy as the maiden offering from the Manipal Group — a brand with significant institutional and retail recognition. Says Anand Rathi Share and Stock Brokers in note: “We believe that the IPO is fully priced and recommend a “Subscribe Long Term” rating to the IPO.”